2014 Jan 1;20(1):221 -32. doi: 10.1158/1078 -0432.CCR -13-1560. 41. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer (2018) 118, 9 –16. doi: 10.1038/bjc.2017.434 42. Kawaguchi T , Ando M , Asami K , Okano Y , Fukuda M , Nakagawa H , et al. Randomized Phase III trial of erlotinib versus docetaxel as second - or third -line therapy in patients with advanced non -small cell lung cancer: doc etaxel and erlotinib lung cancer trial (DELTA). J Clin Oncol.